Sulfonylurea News and Research

RSS
Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting

Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Exenatide tQT clinical trial meets pre-specified primary endpoint

Exenatide tQT clinical trial meets pre-specified primary endpoint

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

EMA CHMP recommends approval of linagliptin for type 2 diabetes

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly responds to Amylin's exenatide lawsuit

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

China's SFDA approves TPI anti-diabetic drug Gliclazide

China's SFDA approves TPI anti-diabetic drug Gliclazide

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Takeda receives Japanese approval for additional indications for NESINA

Takeda receives Japanese approval for additional indications for NESINA